 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| AZD0305 / AstraZeneca
Enrollment change, Combination therapy, Monotherapy: AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 21, 2024
P1/2, N=84, Recruiting, Sponsor: AstraZeneca
N=64 --> 84
- ||| AZD0305 / AstraZeneca
Enrollment open, Combination therapy, Monotherapy: AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 15, 2023
P1/2, N=64, Recruiting, Sponsor: AstraZeneca
N=64 --> 84 Not yet recruiting --> Recruiting
- | AZD0305 / AstraZeneca
Enrollment change, Trial withdrawal: Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases (clinicaltrials.gov) - Nov 18, 2023
P1/2, N=0, Withdrawn, Sponsor: LaNova Medicines Limited
Not yet recruiting --> Recruiting N=380 --> 0 | Not yet recruiting --> Withdrawn
- |||| AZD0305 / AstraZeneca
New P1/2 trial, Combination therapy, Monotherapy: AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 29, 2023
P1/2, N=64, Not yet recruiting, Sponsor: AstraZeneca
- ||||| AZD0305 / AstraZeneca
New P1/2 trial: Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases (clinicaltrials.gov) - Dec 12, 2022
P1/2, N=380, Not yet recruiting, Sponsor: LaNova Medicines Limited